Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
BIOLOGICAL: Sintilimab|DRUG: Lenvatinib
Objective Response Rate (ORR), 1 year after the last patient's enrollment
Overall Survival, 2 years after the last patient's enrollment|Safety of combination sintilimab and lenvatinib as evaluated by incidence of adverse events(AEs), serious adverse events (SAEs)., 2 years after the last patient's enrollment|Conversion rate to surgery, Conversion rate defined as the proportion of participants be able to receive surgery after the initiation of the study treatment, 1 year after the last patient's enrollment|Tumor mutation burden in association with ORR and survival., It will be performed by NGS., 1 year after the last patient's enrollment
This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.